AstraZeneca Says Bydureon Trial Meets Safety Objectives; No Significant CV Reduction
May 23 2017 - 2:49AM
Dow Jones News
By Ian Walker
LONDON--Pharmaceutical giant AstraZeneca PLC (AZN) said Tuesday
that a recent trial of Bydureon met the primary safety objectives
to not increase cardiovascular risk for patients with Type-2
diabetes.
However, Astra said that while cardiovascular events were
observed in the trial, the object of reducing cardiovascular risk
wasn't statistically significant.
-Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749
(END) Dow Jones Newswires
May 23, 2017 02:34 ET (06:34 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024